Literature DB >> 24727316

Bevacizumab for glioblastoma: what can we learn from patterns of progression?

Patrick Y Wen1, Larry Junck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24727316     DOI： 10.1212/WNL.0000000000000421

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas.

Authors:  Byung Sup Kim; Sung Kwon Kim; Seung Hong Choi; Se-Hoon Lee; Ho Jun Seol; Do-Hyun Nam; Jung-Il Lee; Chul-Kee Park; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2015-05-31       Impact factor: 4.130

Review 2.  Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

Authors:  E Antonio Chiocca; Farshad Nassiri; Justin Wang; Pierpaolo Peruzzi; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

3.  Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.

Authors:  Elodie A Pérès; Aurélie N Gérault; Samuel Valable; Simon Roussel; Jérôme Toutain; Didier Divoux; Jean-Sébastien Guillamo; Marc Sanson; Myriam Bernaudin; Edwige Petit
Journal:  Oncotarget       Date:  2015-02-10

4.  Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.

Authors:  Elizabeth Scribner; Olivier Saut; Paula Province; Asim Bag; Thierry Colin; Hassan M Fathallah-Shaykh
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

5.  Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.

Authors:  Fabio Raman; Elizabeth Scribner; Olivier Saut; Cornelia Wenger; Thierry Colin; Hassan M Fathallah-Shaykh
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.